CRISPR Therapeutics (CRSP)
NASDAQ: CRSP · Biotechnology—Gene Editing · Zug,
Our rating: Cautious
Cautious reaffirmed at $49.99, moderate conviction, November 3, 2026.
Breaks if: The cautious call is proved wrong if Casgevy-related revenue — royalties and milestones combined — exceeds $60M in any single reported quarter within the next four quarters. That level of commercial throughput would signal the slow-ramp thesis has broken and would warrant reassessing to at least Neutral. On the price side, if CRSP holds above $70 for six consecutive months without a corresponding revenue inflection, the market is pricing a pipeline catalyst not yet visible in the filings and the call requires re-examination.
Key figures
| Market value | $3.8B |
|---|---|
| Revenue, last 12 months | $25M |
| Net income, last 12 months | −$456M |
| Free cash flow, last 12 months | −$377M |
| Price to earnings | n/a |
| Free cash flow yield | −9.9% |
| Dividend yield | 0.0% |
| Operating margin | −2114.8% |
| Return on equity | −25.6% |
| Beta to the S&P 500 | 1.46 |
| Volatility, annualized | 58.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $13M | 1325.1% | $-1.15 | −$90M |
| June 30, 2026 | $10M | 1041.4% | $-0.94 | −$84M |
| March 31, 2026 | $1M | 68.6% | $-1.28 | −$109M |
| December 31, 2025 | $864000.00 | −97.6% | $-1.35 | −$93M |
| September 30, 2025 | $889000.00 | 47.7% | $-1.17 | −$85M |
| June 30, 2025 | $892000.00 | 72.5% | $-2.40 | −$114M |
| March 31, 2025 | $865000.00 | 71.6% | $-1.58 | −$54M |
| December 31, 2024 | $36M | −82.3% | $-0.42 | −$50M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.01B: Claude 62%, Gemini 90%, Mistral 65%
- Diluted earnings per share are above zero: Claude 4%, Gemini 5%, Mistral 5%
- Free cash flow for the quarter is above zero: Claude 5%, Gemini 5%, Mistral 5%
21 ledger entries and 48 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.